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Background
The safety and the efficacy of allergen specific Immu-
notherapy by subcutaneous route in perennial conjuncti-
vitis caused by house dust mite were evaluated in 89
patients for 24 months.
Methods
Group of 89 patients diagnosed by ophthalmologist
included in study. Patients of allergic conjunctivitis
included in this study underwent Skin allergy test and spe-
cific IgE tests for dust mite allergens. Out of 89 patients
43 received Allergen specific Immunotherapy (SIT) subcu-
taneous injections with standardized Dermatophgoides
farinae (D.f.) and Dermatophagoides pteronyssinus (D.pt.)
allergen extract. While 46 patients are only treated by con-
ventional treatment by using local steroids and antihista-
minic drops. The vaccine was supplied by a commercial
company as per the prescription for each patient. The sub-
jects generally received three concentrations of antigens
ending with the most concentrated solution. Later on,
maintenance immunotherapy was continued with the 1:50
concentration for 24 months. Results were evaluated on 2,
6, 12, 18 and 24 months by using Total Symptom Score
(TSS), Local Medication use, Clinical examination grading,
Quality of Life evaluation (QOL).
Results
Of the 89 patients included, only 81 completed the study
(43 in the Immunotherapy group and 46 in the Non
Immunotherapy group). Three out of 43 (6.9%) patients
dropped out because of insufficient efficacy in the Immu-
notherapy group compared to five out of 46 (10.8%) in
the non immunotherapy group. Sum of all four primary
end point criterias are scored against five group of effi-
cacy evalution. No improvement 8 (9.8% ), marginal
improvement 16 (19.7%), improvement 23 (28.3%) and
significant improvement 35 (43.2%). In group of 35
improved patients 26 (74.2%) were received immunother-
apy while 9 (25.7%) patients did not.
Conclusions
Two years treatment with subcutaneous house dust mite
immunotherapy significantly reduced symptoms and med-
ication use in allergic conjunctivitis patients. This was
associated with a greater subjective improvement and
quality of life in patients of perennial conjunctivitis caused
by house dust mites.
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